Trade Mark Journal No.2026/021 22 May 2026

UK00004381693 1 May 2026 (5)

JEMLITSY

International priority date claimed: 29 April 2026 (United States of America) (99795572)

Class 5: Pharmaceutical preparations for the treatment of autoimmune diseases and disorders; Pharmaceutical preparations for the treatment of immune system diseases and disorders; antibodies for the treatment of immune system diseases and disorders; antibodies for the treatment of autoimmune diseases and disorders.

Biogen MA Inc.

Representative: Finnegan Europe LLP